Atrasentan Hydrochloride Patent Expiration
Atrasentan Hydrochloride was first introduced by Novartis Pharmaceuticals Corp
Atrasentan Hydrochloride Patents
Given below is the list of patents protecting Atrasentan Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vanrafia | US11491137 | Methods of improving renal function | Dec 16, 2040 | Novartis |
| Vanrafia | US11998526 | Methods of improving renal function | Dec 16, 2040 | Novartis |
| Vanrafia | US12121509 | Methods of improving renal function | Dec 16, 2040 | Novartis |
| Vanrafia | US10016393 | Stabilized pharmaceutical dosage forms comprising atrasentan | Jul 07, 2034 | Novartis |
| Vanrafia | US9364458 | Stabilized pharmaceutical dosage forms comprising atrasentan | Jul 07, 2034 | Novartis |
| Vanrafia | US11874283 | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases | Feb 18, 2032 | Novartis |
| Vanrafia | US8623819 | Therapy for complications of diabetes | Aug 22, 2028 | Novartis |
Atrasentan Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List